Skip to main content

Table 1 Species drug combinations tested and MIC breakpoints according to DIN 2004 and EUCAST 2.0

From: Impact of minimal inhibitory concentration breakpoints on local cumulative bacterial susceptibility data and antibiotic consumption

  MIC breakpoints (μg/ml)
  DIN EUCAST
Drug S I R S I R
Enterobacteriaceae       
 pip./taz. ≤4 8-32 >32 ≤8 16 >16
 cefotaxime ≤2 4-8 >8 ≤1 2 >2
 imipenema ≤2 4 >4 ≤2 4-8 >8
 ciprofloxacin ≤1 2 >2 ≤0.5 1 >1
 gentamicin ≤1 2-4 >4 ≤2 4 >4
Pseudomonas aeruginosa       
 piperacillin ≤4 8-32 >32 ≤16 >16
 ceftazidime ≤4 8-16 >16 ≤8 >8
 imipenem ≤2 4 >4 ≤4 8 >8
 meropenem ≤2 4-8 >8 ≤2 4-8 >8
 ciprofloxacin ≤1 2 >2 ≤0.5 1 >1
 gentamicin ≤1 2-4 >4 ≤4 >4
Stenotrophomonas maltophilia       
 trim./sulfam. ≤16 32-64 >64 ≤4 >4
 Acinetobacter baumanii       
 imipenem ≤2 4 >4 ≤2 4-8 >8
 meropenem ≤2 4-8 >8 ≤2 4-8 >8
 ciprofloxacin ≤1 2 >2 ≤1 >1
 gentamicin ≤1 2-4 >4 ≤4 >4
Enterococcus spp.       
 ampicillin ≤2 4-8 >8 ≤4 8 >8
 vancomycin ≤4 8 >8 ≤4 >4
 teicoplanin ≤2 >2
 linezolid ≤4 >4
Staphylococcus spp.       
 oxacillinb ≤1 >1 ≤2 >2
 oxacillinc ≤1 >1 ≤0.25 >0.25
 vancomycinb ≤4 8 >8 ≤2 >2
 vancomycinc ≤4 8 >8 ≤4 >4
 teicoplaninb ≤2 >2
 teicoplaninc ≤4 >4
 linezolid ≤4 >4
 rifampicin ≤0.06 >0.5
 clindamycin ≤1 2-4 >4 ≤0.25 0.5 >0.5
  1. aProteus, Morganella, and Providencia spp. were tested against meropenem, bbreakpoints for S. aureus, cbreakpoints for coagulase-negative staphylococci, “─” no data.